PRE-CONFERENCE WORKSHOP DAY | TUESDAY 25TH JANUARY 2022

WORKSHOP A
12.00 - 13.15 GMT

Progress Your Pipeline by Utilising Emerging Technologies

Part 1 - Emerging Understanding of Microbiome Colonization Dynamics and Formulation of LBP's
Recent developments in clinical programs emphasize the importance to understand colonization dynamics and formulation techniques for LBP's. Microbiome pioneers have developed and validated new ways to purify and formulate bacteria or microbiome fractions,
translating the growing insights from clinical and preclinical studies to form the growing understanding of mechanisms of action.
Come aboard this workshop to discover in emerging strategies designed to overcome the new challenges this new modality sets in the preclinical scene.

Highlights include:

  • Learn about the different approaches to understand colonization dynamics and
    engraftment
  • Discover the new formulation approaches to translate these insights into therapeutics

Part 2 - Identifying Drug Targets With Bacterial Single Cell Tools

Highlights include:

  • We will introduce a new single cell tool that can measure the full transcriptome of individual bacterial cells
  • Bacterial cells are highly heterogeneous even in isogenic culture, and many virulence genes are produced only by a subset of cells
  • New single-cell techniques can identify perturbations that may reduce virulence

Tomas de Wouters
CEO
PharmaBiome

Melanie Brennan
Research Associate
IFF

WORKSHOP B
13.45 - 15.00 GMT

Microbiome-based Biomarkers & Patient Stratification

The understanding that the gut microbiome likely plays a central role in immune mediated disease progression is increasingly supported. Therefore microbiomebased biomarkers are increasingly backed in their role in risk stratification and disease prediction. Join this workshop to discover how these biomarkers can show predictive disease activity and resistance to therapy which has extensive clinical benefits.

Highlights include:

  • Exploring case studies of how cross sectional studies using biomarkers can show clear disease linkages
  • Exploring how longitudinal case studies using biomarkers have  given an insight into the predictivity of disease
  • Understand how biomarkers can be robustly validated to amplify this field
  • Learn how these clinical practice will be facilitated by integrating these microbiome biomarkers

Gerard Honig
Crohn's and Colitis Foundation

David Hava
Synlogic

Alena Pribyl
Microba

WORKSHOP C 
15.15 - 16.30 GMT

The Potential Role of Microbiome Therapeutics in Hematopoietic Stem Cell Transplant (HSCT) Patients

Seres Therapeutics is evaluating whether SER-155, an investigational cultivated microbiome therapeutic could reduce the risk of blood stream infections, graft versus host disease and mortality in this patient population.

Highlights include:

  • Observational data suggesting that a low diversity microbiome is associated with risk of poor clinical outcomes
  • In vitro and in vivo drug development data on SER-155
  • Manufacturing process of SER-155 that differentiate it from other FMT products and how it enhances safety in these immunocompromised patients

Chris Ford
Senior Scientist
Seres Therapeutics

Jonathan Peled
Seres Therapeutics

Bina Tejura
Seres Therapeutics